Bucindolol

From Self-sufficiency
Jump to: navigation, search
Bucindolol
File:Bucindolol.png
Systematic (IUPAC) name
2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethyl-ethyl]amino]propoxy]benzonitrile
Identifiers
CAS Number 71119-11-4
ATC code none
PubChem CID 51045
ChemSpider 46266
Chemical data
Formula C22H25N3O2
Molar mass 363.45 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009 but was rejected.[1][3]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


Sympatholytic (and closely related) antihypertensives (C02)
Sympatholytics
(antagonize α-adrenergic
vasoconstriction)
Central
Adrenergic release inhibitors
Peripheral
Indirect
Direct
Non-selective α blocker
Other antagonists
dual (Bosentan) • selective (Ambrisentan, Sitaxentan)


40px This antihypertensive-related article is a stub. You can help ssf by expanding it.
  1. ↑ 1.0 1.1 "formularyjournal.modernmedicine.com". 
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. ↑ "FDA rejects bucindolol and questions trial integrity « CardioBrief". 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Bucindolol&oldid=23897"